Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2001

View Archived Issues

Patient recruitment complete in Cangene's three phase III trials

Ophidian updates merger plan with Hemoxymed

SkyePharma summarizes major achievements over past year

NeoTherapeutics receives U.S. patent for technology with broad therapeutic applications

Vertex reports Q1 2001 results

Antiparkinsonian A-7 blocks open NMDA channels similar to adamantane

PhotoCure seeks marketing approval for Metvix(R) PDT in New Zealand

GlaxoSmithKline Biologics and MVI to initiate pediatric clinical trial of malaria vaccine

Aventis prepares oxindoles as potent inhibitors of cyclin-dependent kinases

Vasogen plans trial of immune modulation therapy for PAD

Medarex and Neuro Therapeutics enter alliance to develop antibody therapeutics

ImClone Systems achieves milestone in BEC2 collaboration with Merck KGaA

Scios updates status, reviews progress of lead products

MX-2060: a novel caspase-activating apoptosis inducer discovered at Maxim

Avant Immunotherapeutics reports highlights for the quarter

IntaBiotics' Protegrin IB-367 rinse meets secondary but not primary endpoints

Progenics and Roche extend HIV therapeutics collaboration

3-D Pharmaceuticals and Boehringer Ingelheim extend drug discovery collaboration

Forbes Medi-Tech provides additional preclinical study results for FM-VP4

Organogenesis provides brief product update

Lilly claims new use of parathyroid hormone

Direct delivery of bFGF shown to be useful in wound healing model

New endothelin receptor antagonists useful for circulatory disorders

New compounds interacting with estrogen receptors useful for menopausal disorders, etc.

Aventis presents new NHE-3 inhibitors

New 5-HT6 receptor modulators useful for CNS disorders patented by Pharmacia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...